Condition: Mitral Regurgitation Functional · Sponsor: Hangzhou Valgen Medtech Co., Ltd
To confirm the effectiveness and safety of the Dragonfly transcatheter mitral valve repair system for the treatment of chronic moderate to severe (3+) or severe (4+) functional mitral regurgitation (FMR) who remained clinically symptomatic after guideline-directed medical treatment.
This description comes directly from the study's public registry record.
Jing Dai · +8617710418660 · jing.dai@valgenmed.com
Shuangjie Li · +8617756106609 · shuangjie.li@valgenmed.com
Always discuss trial participation with your own doctor first.
| The Second Affiliated Hospital Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04733404